HORMONE/FDA APPROVED
Tesamorelin (Egrifta)
Subcutaneous injection
Overview
A synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways.
Mechanism of Action
It is the only FDA-approved treatment for HIV-associated lipodystrophy.
​Research Summary & Key Findings
FDA-approved in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials showed 15-18% reduction in visceral adipose tissue. Also demonstrated improvements in liver fat content in patients with NAFLD in Phase 2 studies.
Clinical Status
FDA APPROVED
Tesamorelin (Egrifta) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
Subcutaneous injection (weekly)
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.